AmSurg Shares Rise in Value After $2.35B Sheridan Deal Announcement

Raymond James analyst John Ransom set AmSurg’s price target at $60 and upgraded his recommendation to “buy,” according to a Value Walk report.

The upgrade was made closely following AmSurg’s announcement of intention to acquire Sheridan Healthcare for $2.35 billion.

More Articles on Transactions and Valuation Issues:
4 Recent ASC Industry Acquisitions
Beloit Health System ASC Project Remains in Limbo
3 Recently Opened & Expanded Ambulatory Surgery Centers

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers

Featured Podcast